Eurocor Tech

#Sobrice2024 #Freeway - Eurocor Tech

Freeway’s ™ industry leading long-term Efficacy and outstanding long-term Safety 

Objectives: To study the safety and short and intermediate term efficacy of drug-eluting balloon (DEB) in the treatment of de-novo and in-stent restenotic coronary artery disease (CAD). Conclusion: Drug-coated balloons appear to be effective versus control in reducing TLR and possibly MI versus balloon angioplasty or drug-eluting stents in the management of ISR. #DiorDilationRestenosis Eurocor Tech https://lnkd.in/dawk2iFQ

#cirurgiavascular SBACV - Sociedade Brasileira de Angiologia e de Cirurgia Vascular

#FREEWAY™ 014 SEGURANÇA E EFICÁCIA COMPROVADAS Eurocor Tech na mãos do Marcelo Giusti e também disponível em todo Brasil! Marcos Mascarenhas

We are happy to announce that Eurocor’s 5-year FREEWAY™ safety and efficacy data was presented at the LINC 2024 conference in Leipzig, Germany by Dr. Marcelo Giusti (Hospital do Coração, Sao Paulo Brazil). The presentation is titled: "Five-year follow-up and mortality of patients of the randomized Freeway Stent Study" in the session titled: "Update on latest data and ongoing trials: Original abstracts femoropopliteal disease". The entire program can be viewed under the following link: https://lnkd.in/dkXbNf5 Mm Medical Produtos Medicos E Hospitalares Marcos Mascarenhas #Freeway #cirurgiavascular SBACV - Sociedade Brasileira de Angiologia e de Cirurgia Vascular #LINC Hcor - Hospital do Coração  

Toda nossa solidariedade e força ao povo Gaúcho! Toda doação é bem vinda! All our solidarity and strength to the people of Rio Grande do Sul! Every donation is welcome!

We are happy to announce that Eurocor’s 5-year FREEWAY™ safety and efficacy data will be presented at the LINC 2024 conference in Leipzig, Germany by Dr. Marcelo Franchini Giusti (Hospital do Coração, Sao Paolo Brazil). The presentation is titled: "Five-year follow-up and mortality of patients of the randomized Freeway Stent Study" and will take place on Wednesday, May the 29th, at 16:45. The LINC annual congress features state-of-the-art lectures and live cases from leading interventional centers. The event is open to a global audience of health care professionals ranging from cardiologists to radiologists and vascular surgeons.   Temos o prazer de anunciar que os dados de segurança e eficácia FREEWAY™ de 5 anos da Eurocor serão apresentados na conferência #LINC2024 em Leipzig, Alemanha pelo Marcelo Giusti (Hospital do Coração, São Paulo Brasil). A apresentação intitula-se: "Seguimento de cinco anos do estudo randomizado #Freeway Stent Study" e acontecerá na quarta-feira, dia 29 de maio, às 16h45. Eurocor Tech GmbH #DEB #segurança #eficácia.

 O estudo do Prof. Yildiz : "A eficácia da angioplastia com balão farmacológico com paclitaxel versus angioplastia com balão padrão na estenose de fístulas arteriovenosas de hemodiálise nativa: uma análise do sucesso clínico, perviedade primária e fatores de risco para disfunção recorrente." Included 96 hemodialysis patients (32 FREEWAY™ – 64 PTA) and found a significantly higher primary patency rate at 6 months for patients treated with FREEWAY DEB (96.9% DEB vs 20.3% PTA p<0.001). Other favorable findings included longer median fistula survival with FREEWAY (220 days) compared to standard PTA balloon treatment (152.5 days) and less recurrence of fistula dysfunction (21.9% DEB vs. 31.3% PTA). This data strongly supports the positive findings from the other cited FREEWAY AV studies, such as a significantly higher primary patency rate at 12 months and significantly longer mean fistula survival (Çildağ et al. 2016) or significantly longer time to re-intervention after FREEWAY DEB compared to standard PTA treatment (Troisi et al. 2018) and a very low re-intervention rate at follow-up (Duda et al. 2015), and underscore the benefits of FREEWAY DEB fistula treatment, especially the quality-of-life improvements for hemodialysis patients. Please contact us for a specific training based on scientific evidence on how FREEWAY AV can improve the treatment of AV fistula patients. 

No Dia Mundial da Saúde, a SBACV reafirma seu objetivo em propiciar e intensificar o estudo da nossa especialidade, promovendo o conhecimento sobre a saúde vascular à todos os indivíduos. #DiaMundialdaSaúde